GoodRx Holdings, Inc. - Class A Common Stock (GDRX)

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx’s condition-specific telemedicine solutions, integrating clinical care, prescribing, and pharmacy fulfillment to help employees access high-impact brand medications without traditional formulary blockers. Designed to complement, not replace, traditional health plans, Employer Direct gives employers a scalable, cost-conscious way to improve affordability without adding plan complexity.

Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

GoodRx’s stock price has taken a beating over the past six months, shedding 56.5% of its value and falling to $2.23 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 17.3% gain over the past six months, beating the S&P 500 by 8.1 percentage points.

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx.

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx’s prior HITRUST achievement and underscores the company’s ongoing commitment to safeguarding sensitive healthcare information.

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx (NASDAQ:GDRX) and its peers.

Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to transform the medication experience and empower patients by bringing together prescription benefit data, medication management and personalized engagement. Script Corner will include patient price transparency, including discounted cash prices through an exclusive partnership with GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S.

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access lower prices on high-cost brand medications directly at the pharmacy counter.

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to the medication, they will soon be able to connect with a licensed healthcare provider through GoodRx for Weight Loss to determine eligibility and obtain a prescription when appropriate. The arrival of the Wegovy pill on GoodRx represents a significant step forward in making GLP-1 treatments more affordable and accessible for people looking to begin or advance their weight-loss journey.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.5% over the past six months, topping the S&P 500 by 2.5 percentage points.

GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which GoodRx will discuss business updates.

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) fell 1.7% in the afternoon session after Barclays initiated coverage on the health-focused technology company with an "Underweight" rating and a $3 price target. The "Underweight" rating from analyst Glen Santangelo suggested a negative outlook for the stock's performance. This new rating came amidst a series of recent cautious views from other financial institutions. For instance, BofA had previously cut its price target on the stock to $3, and JPMorgan analysts also brought their price target down. This pattern showed a broader concern among analysts regarding the company's near-term outlook.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.